2hon MSN
With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Investor's Business Daily on MSN3h
IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat EarningsCompounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback